Medicare billing address
CMS Medicare provider billing file
1259 S Cedar Crest Blvd Ste 100Allentown, PA 18103
CMS public data · NPI 1376549386
CMS public files list billing, prescribing, location, and participation fields for this NPI. Current plan networks, appointment availability, clinical outcomes, and patient-specific medical advice require separate verification.
CMS display name
Marvin Sasson, M.D.
Specialty
Credential
M.D.
NPI
1376549386
Primary source state
PA
Data retrieval date
July 26, 2026
Where these numbers come from, and what they cannot tell you
Public CMS records, 2024 reporting year. These are historical Medicare fields, not proof of current coverage, appointment availability, quality, or what someone will pay.
This page shows Medicare billing and Part D prescribing data for Marvin Sasson, M.D. from CMS public files. It covers 2024 claims data: services billed, the beneficiary panel, and the most-prescribed Part D drugs. It does not show current coverage, appointment availability, or quality ratings.
A licensed agent, not a call center
Peter Abilla, Licensed Medicare Insurance Sales Agent, NPN 22265186. Bring the doctors and prescriptions that matter to you, then check the details before you enroll.
Medicare participating
Yes
Individual assignment
Yes
Group assignment
Yes
CMS opt-out records
0
When CMS files list more than one address for the same NPI, each address stays tied to the CMS file that reported it.
CMS Medicare provider billing file
1259 S Cedar Crest Blvd Ste 100CMS Doctors & Clinicians file
1259 S Cedar Crest BlvdCMS Doctors & Clinicians file
400 N 17Th StCMS Doctors & Clinicians file
401 N 17Th StIn the 2024 CMS provider billing file, this NPI had 1,657 Medicare beneficiaries and 6,495 total services. The average beneficiary age was 75, and the average HCC risk score was 1.
Total Medicare allowed amount
$362,148.51
Total Medicare payment amount
$253,767.44
Medicare beneficiaries
1,657
Total services
6,495
These percentages describe the Medicare beneficiary panel in the CMS utilization file. They are not a diagnosis for any individual patient and are not a quality score.
Hyperlipidemia
75%
CMS beneficiary-panel share
Hypertension
70%
CMS beneficiary-panel share
Ischemic heart disease
24%
CMS beneficiary-panel share
Chronic kidney disease
23%
CMS beneficiary-panel share
Diabetes
22%
CMS beneficiary-panel share
Anxiety
22%
CMS beneficiary-panel share
Where these service numbers come from, and what they cannot tell you
Amounts shown are average Medicare-approved amounts per billed unit in CMS records. What a person pays depends on current coverage and cannot be read from this table alone.
| CMS service description | Services | Avg allowed |
|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 1,742 | $6.14 |
| Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more | 1,564 | $85.80 |
| Destruction of precancer skin growth, 1 growth | 717 | $49.63 |
| Biopsy of related skin growth, first growth | 475 | $85.67 |
| Destruction of skin growth, 1-14 growths | 359 | $103.83 |
| Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more | 194 | $120.90 |
| New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more | 133 | $104.21 |
| Established patient office or other outpatient visit with straightforward medical decision making, if using time, 10 minutes or more | 103 | $53.24 |
| Biopsy of related skin growth, each additional growth | 93 | $46.61 |
| Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | 59 | $155.59 |
Where these Part D numbers come from, and what they cannot tell you
CMS data reports historical prescription drug events attributed to NPI 1376549386. Formularies, copays, prior authorization, and step therapy rules vary by current coverage.
| Rank | Drug | Generic name | Total claims | 30-day fills | Total drug cost |
|---|---|---|---|---|---|
| 1 | Ketoconazole | Ketoconazole | 337 | 415.2 | $6,425.34 |
| 2 | Fluorouracil | Fluorouracil | 187 | 190 | $12,228.02 |
| 3 | Triamcinolone Acetonide | Triamcinolone Acetonide | 154 | 171 | $2,077.10 |
| 4 | Hydrocortisone | Hydrocortisone | 113 | 119 | $559.55 |
| 5 | Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 80 | 84 | $1,750.04 |
| 6 | Metronidazole | Metronidazole | 77 | 88.1 | $4,223.67 |
| 7 | Doxycycline Hyclate | Doxycycline Hyclate | 66 | 150.3 | $4,019.83 |
| 8 | Fluocinonide | Fluocinonide | 54 | 59 | $2,299.64 |
| 9 | Mupirocin | Mupirocin | 49 | 53 | $420.91 |
| 10 | Clindamycin Phosphate | Clindamycin Phosphate | 38 | 45 | $1,922.59 |
CMS Part D records are historical aggregate claims data. They do not include current formulary status, pharmacy price, prior-authorization rules, network-directory status, or clinical-outcome data.
Medical school
New York University School Of Medicine
Graduation year
1993
Group/practice field
Advanced Dermatology Associates, Ltd.
Telehealth reported
Not reported
Verify plan-directory status, drug formulary rules, pharmacy pricing, appointment availability, and clinical questions against current plan documents and the relevant provider or care team.
The numbers above come from CMS public-use files for this NPI. Each link identifies the CMS release used and the retrieval date.